⌕
Abivax · ABVX · Nasdaq
Tenet — · insufficient data
Compare
$83.61−4.53%At close
$83.61−3.97 (−4.53%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Abivax (ABVX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 15, 2026 · 09:53 ET
85,000 Shares of Abivax SA Sponsored ADR $ABVX Acquired by ACT Capital Partners L.P.

ACT Capital Partners L.P. acquired a new position in shares of Abivax SA Sponsored ADR (NASDAQ: ABVX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institu…

● GlobeNewsWireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Abivax to Participate in Upcoming Fall Investor Conferences

Abivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage b…

● Seeking AlphaSep 23, 2026 · 13:00 ET
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts

Abivax Société Anonyme is advancing obefazimod for ulcerative colitis and Crohn's, with recent safety concerns now largely addressed. ABVX raised $920 million, extending its cash runway into Q4 2029 and strengthening its…

● BenzingaSep 22, 2026 · 09:28 ET
These Analysts Slash Their Forecasts On Abivax Following H1 Results

Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.…

● GlobeNewsWireSep 21, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax Presents Business Updates and First Half 2026 Financial Results  Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness a…

● Defense WorldSep 21, 2026 · 02:15 ET
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by Brokerages

Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the sixteen research firms that are currently covering the company, MarketBeat.com reports. One equities res…

● BenzingaSep 21, 2026 · 02:06 ET
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:…

● Zacks Investment ResearchSep 18, 2026 · 13:35 ET
4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.…

● BenzingaSep 14, 2026 · 04:55 ET
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

ABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the closing bell on Monday, Sept. 21.…

● Zacks Investment ResearchSep 8, 2026 · 13:00 ET
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

● Defense WorldAug 27, 2026 · 02:16 ET
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat reports. One research ana…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ABVX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.